Peter Edward Fecci

Peter Edward Fecci
Assistant Professor of Neurosurgery
Third Year Mentor - Molmed - Molecular Basis of Disease Study Track
Third Year Mentor - Neurosciences Study Program (NSS)
Campus mail: 201 Sands Bldg., Box 3050, Durham, NC 27710
Phone: (919) 681-1010

Education and Training

  • Duke University School of Medicine, M.D. 2007
  • Duke University, Ph.D. 2007
  • Massachusetts General Hospital, Internship, General Surgery
  • Massachusetts General Hospital, Residency, Neurosurgery
  • Dana Farber Cancer Institute, Postdoctoral Fellow
  • Massachusetts General Hospital, Instructor, Neurosurgery


Immune Constitution of Patients with Brain Tumors

© 2017 Elsevier Inc. All rights reserved. Immune deficiencies in patients with glioblastoma (GBM) are not a new discovery. Researchers have been perplexed and challenged by impairments to immunity in the context of GBM dating back to the 1970s.

Immunotherapy for malignant glioma.

Malignant gliomas (MG) are the most common type of primary malignant brain tumor. Most patients diagnosed with glioblastoma (GBM), the most common and malignant glial tumor, die within 12-15 months.

Immunotherapy of malignant brain tumors.

Despite aggressive multi-modality therapy including surgery, radiation, and chemotherapy, the prognosis for patients with malignant primary brain tumors remains very poor.

Immunovirotherapy for the treatment of glioblastoma

We have recently described a new murine model of glioblastoma, generated by the implantation of syngeneic glioblastoma stem cells into immunocompetent mice, that recapitulates the salient histopathological and immunological features of the human d